Natera’s Q2 2026: Test Volumes Surge, Margins Grow, and the Revenue Forecast Revisions Hint at a Bigger 2026

Overview: Revenue Strength Meets Margin Momentum

Natera disclosed total revenues of $752.8 million for the quarter ended June 30, 2026, up from $546.6 million in the prior-year period. The growth rests on stronger volumes and, according to management, improvements in average selling prices. GAAP gross profit reached $485.2 million, corresponding to a gross margin of 64.5% versus 63.4% in Q2 2025. Excluding revenue true-ups, the company noted a non-GAAP gross margin improvement of 50 basis points versus the first quarter of 2026, underscoring an operational lift in the cost of revenues line as volumes rise.

On the testing front, Natera processed approximately 1,043,900 tests in the quarter, with about 1,030,100 tests accessioned in its laboratory, up from roughly 853,100 processed and 839,300 accessioned in Q2 2025. Oncology-specific testing was robust too, with approximately 296,700 oncology tests processed in Q2 2026. Management framed MRD oncology units as a source of continued growth, noting a sequential increase of 34,000 units over Q1 2026—the largest such gain to date.

In line with a normalization narrative around volume-led growth, the company highlighted other operational highlights, including a roughly $3.6 million increase in cash during the quarter. The tone suggests the business is not merely punching above its weight in top-line growth, but also transferring that momentum into cash generation—an important signal for investors who track cash flow strength alongside revenues.

Key Highlights at a Glance

• Revenue: $752.8 million in Q2 2026; up 37.7% year over year.
• Gross margin: GAAP 64.5% (vs. 63.4% in Q2 2025); non-GAAP gross margin rose 50 bps vs Q1 2026 (excluding revenue true-ups).
• Testing volumes: ~1.0439 million tests processed; ~1.0301 million accessioned.
• Oncology testing: ~296.7k oncology tests in Q2 2026.
• MRD momentum: 34k MRD oncology units sequentially added from Q1 2026—the strongest quarter-to-quarter rise to date.
• Cash position: Cash increased by approximately $3.6 million in the quarter.
• Guidance: Raised 2026 revenue midpoint by $100 million to a new range of $2.85 billion to $2.91 billion.

Outlook and Strategic Context

The revenue guidance bump signals management confidence in the demand trajectory and operational leverage as testing volumes continue to scale. The mid-year lift to the 2026 revenue forecast suggests a broader belief that the mix—strong volumes, favorable pricing, and higher-margin services—will persist through the second half of the year.

Strategic milestones referenced in the release—Signatera regulatory approvals, Medicare coverage expansion for Prospera, and a notable Panorama NIPT enhancement—point to a multi-pronged growth strategy. These developments could broaden the addressable market and improve payer mix, potentially supporting premium pricing or expanded adoption in the lab testing ecosystem.

From a cash and cost perspective, the improvement in gross margin alongside cost-reduction progress in the cost of revenues paints a picture of not just higher top-line performance, but more efficient operations. This matters for EPS trajectory, even if the release does not provide an explicit EPS figure in this quarter’s materials. In the language of investors who parse earnings calls, the question becomes whether the improved gross margin and volume gains translate into a durable earnings per share path that meets or exceeds the EPS consensus and any earnings surprise expectations.

What This Might Portend for Natera and Sector Peers

Matt Levine would note that the story here is less about a one-off beat and more about the slope of scale: greater testing volumes paired with margin discipline create a pathway to stronger profitability even as the company invests in growth initiatives. The combination of MRD-driven oncology demand, Signatera’s regulatory momentum, and coverage expansions for Prospera expands the company’s platform leverage. If these factors persist, Natera could sustain a multi-quarter revenue cadence that broadens its earnings narrative beyond the next quarterly release.

For sector peers, the signal is twofold. First, payer coverage and regulatory clearances that widen the addressable market can lift adoption curves for cfDNA testing and related platforms. Second, the ability to convert volume growth into margin improvement—especially when cost of revenues declines as processing scale improves—becomes a template for how other players might manage the classic revenue-versus-margin trade-off in a high-volume diagnostic business. In short, the playbook is shifting from “more tests” to “more tests with better margins.”

Investors will be watching several live wires: the EPS trajectory (and the corresponding EPS consensus on the next call), the degree to which the revenue forecast refresh proves durable, and whether further operational improvements can sustain or extend the margin gains. If earnings surprises reappear on the upside or if the company sustains double-digit revenue growth with improving margins, the stock could reflect a re-rating as the market prices in a longer-duration growth story rather than a quarterly breath of momentum.

Risks and Considerations for Investors

Key unknowns include the pace of payer adoption, the sustainability of ASP improvements, and potential shifts in regulatory or reimbursement landscapes that could alter the revenue mix. A material shift in testing volumes, lab capacity constraints, or faster-than-expected cost growth could dampen the margin trajectory. As always, the presence or absence of a clearly disclosed EPS figure and the degree to which the company revises its revenue forecast will influence the stock’s responsiveness to quarterly disclosures.

Takeaway: A Growth-First Quarter with a More Confident Revenue Path

Natera’s Q2 2026 results present a narrative of scale—the kind of momentum that can sustain a higher revenue forecast. The combination of robust testing volumes, strong gross margins, and strategic platform expansions creates an optimism about sequencing leverage in a high-demand market. For readers tracking earnings indicators, the immediate next checkpoint will be the EPS data and how the market interprets the revenue forecast refinement in the context of an evolving competitive and regulatory landscape.

As with any disclosure in this space, the true test will be whether the trajectory translates into sustained profitability. In the meantime, NTRA has given investors a reason to keep listening—not just to the loud numbers, but to the quiet undercurrent of efficiency and market expansion that could, over time, redefine what “growth” looks like in this segment.